TIDMTILS

RNS Number : 1475I

Tiziana Life Sciences PLC

10 December 2020

Tiziana Life Sciences PLC

("Tiziana" or the "Company")

PDMR Dealing

London, New York, 10 December 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 35,000 ordinary shares of 3p each in the market at a price of 78p per share.

The acquisition takes Mr Cerrone's interests from 34.052% to 34.070% (within the 1% incremental threshold under Note 11 to Rule 9 of the UK Takeover Code).

 
 1.    Details of PDMR / person closely associated 
 a)    Name                Gabriele Cerrone 
      ------------------  ------------------------------------------------- 
 2.    Reason for the notification 
      --------------------------------------------------------------------- 
 a)    Position            Executive Chairman 
        / status 
      ------------------  ------------------------------------------------- 
 b)    Initial             Initial notification 
        notification 
        /amendment 
      ------------------  ------------------------------------------------- 
 3.    Details of the issuer 
      --------------------------------------------------------------------- 
 a)    Name                Tiziana Life Sciences plc 
      ------------------  ------------------------------------------------- 
 b)    LEI                 213800CED47HI8PIOB36 
      ------------------  ------------------------------------------------- 
 4.    Details of the transaction(s): section to be repeated for 
        (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions have 
        been conducted 
      --------------------------------------------------------------------- 
 a)    Description         Ordinary Shares of 3p each 
        of the 
        financial 
        instrument 
      ------------------  ------------------------------------------------- 
 b)    Identification      ISIN for Tiziana Life Sciences plc: GB00BKWNZY55 
        code of 
        the Financial 
        Instrument 
      ------------------  ------------------------------------------------- 
 c)    Nature              Market Purchase 
        of the 
        transaction 
      ------------------  ------------------------------------------------- 
       Price(s)            78p 
 d)     and volume(s)       35,000 
      ------------------  ------------------------------------------------- 
 f)    Date of             9 December 2020 
        the transaction 
      ------------------  ------------------------------------------------- 
 g)    Place of            XLON 
        the transaction 
      ------------------  -------------------------------------------------

About Tiziana Life Sciences

Tiziana Life Sciences plc is a dual listed (NASDAQ: TLSA & UK AIMS: TILS) biotechnology company that focuses on the discovery and development of novel molecules to treat human diseases in oncology, inflammation and infectious diseases. In addition to milciclib, the Company will be shortly initiating phase 2 studies with orally administered foralumab for Crohn's Disease and nasally administered foralumab for progressive multiple sclerosis. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) in clinical development in the world. This phase II compound has potential application in a wide range of autoimmune and inflammatory diseases, such as Crohn's Disease, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. The person who arranged the release of this information is Keeren Shah, Finance Director of Tiziana.

For further enquiries:

United Kingdom Investors:

 
 Tiziana Life Sciences plc 
  Gabriele Cerrone, Chairman and founder    +44 (0)20 7495 2379 
 Cairn Financial Advisers LLP (Nominated 
  Adviser) 
  Liam Murray / Jo Turner                   +44 (0)20 7213 0880 
 Optiva Securities Limited (Broker) 
  Robert Emmet                              + 44 (0)20 3981 4173

United States Investors:

 
 Dave Gentry               Office 1 800 RED CHIP (733 
  RedChip Companies Inc.    2447) 
                            Cell 407-491-4498 (USA) 
                            dave@redchip.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHDDBDDRUGDGGC

(END) Dow Jones Newswires

December 10, 2020 02:00 ET (07:00 GMT)

Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Tiziana Life Sciences Charts.
Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Tiziana Life Sciences Charts.